Streetbeat News

Equity Actions

AJG

Arthur J. Gallagher & Co. has announced an increase in its quarterly cash dividend from $0.55 to $0.60 per share, signaling confidence in its financial stability and commitment to returning value to shareholders.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 9:32 pm

CASH

Pathward Financial has reaffirmed its fiscal year 2024 GAAP earnings per share (EPS) guidance to be between $6.20 and $6.70. The company also expects its annual tax rate to be between 16% and 20%.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 9:16 pm

TSLA

Tesla has announced that it has enough liquidity to fund its product roadmap, long-term capacity expansion plans, and other expenses. The company also intends to manage its business to maintain a strong balance sheet during the current uncertain period.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 9:08 pm

JNJ

Johnson & Johnson (NYSE:JNJ) has been evaluated by 12 analysts over the last three months, with a mix of bullish and indifferent sentiments. The average 12-month price target is $191.83, up from the previous $172.50. Analysts from firms like Morgan Stanley, Cantor Fitzgerald, RBC Capital, Raymond James, Wells Fargo, and UBS have provided various ratings and price target adjustments. Johnson & Johnson is a large healthcare firm with pharmaceutical, medical devices, diagnostics, and consumer divisions, with the consumer group set to be divested in 2023. The company has shown strong financial performance with a high net margin of 121.91% and ROE of 35.56%, but its revenue growth rate of 6.78% is below the Health Care sector average.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 9:01 pm

INGN

Inogen, a medical technology company, has appointed Michael Bourque as its new Chief Financial Officer (CFO), effective March 4, 2024. This executive change is part of Inogen's ongoing efforts to strengthen its leadership team and drive future growth.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 9:01 pm

AMT

American Tower (NYSE:AMT) received mixed analyst ratings with 1 bullish and 3 somewhat bullish in the past three months. The average 12-month price target is $227.25, up from the previous $213.33. Analysts from Barclays, HSBC, RBC Capital, and JP Morgan have provided recent evaluations, with price target adjustments reflecting a positive outlook despite some lowering of targets. American Tower, an REIT, operates over 220,000 cell towers globally and 28 data centers in the US. The company's financial performance shows solid revenue growth, high net margin, and ROE, but a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 9:01 pm

EQIX

Equinix (NASDAQ:EQIX) has been reviewed by 4 analysts over the past three months, with mixed sentiments. The average 12-month price target is $836.25, a 5.59% increase from the previous target. Analysts from Barclays, Truist Securities, Morgan Stanley, and Oppenheimer have adjusted their ratings and price targets. Equinix operates 248 data centers globally and serves over 10,000 customers. Financially, it has shown revenue growth but has below-average net margin and ROE, with a strong ROA and a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 9:00 pm

ONB

Old National Bancorp (NASDAQ:ONB) has been analyzed by four analysts in the last quarter, with mixed opinions ranging from bullish to bearish. The average 12-month price target is $18.25, with a high of $21.00 and a low of $16.00, marking a 7.22% decrease in the average target. Analysts from Stephens & Co., UBS, Citigroup, and Piper Sandler have adjusted their ratings and price targets. Old National, a financial services bank holding company, has shown a slight decline in revenue growth, an impressive net margin of 31.54%, a strong ROE of 2.86%, and an ROA of 0.29%, but carries a higher debt-to-equity ratio of 1.09.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 9:00 pm

COP

Analysts have provided mixed reviews on ConocoPhillips (NYSE:COP) over the past three months, with ratings ranging from bullish to indifferent. The average 12-month price target is $137.17, with a high of $141.00 and a low of $132.00, marking a 3.96% decrease from the previous average. Recent actions include both lowered and raised price targets by analysts from firms such as Raymond James, Mizuho, UBS, JP Morgan, and RBC Capital. ConocoPhillips is a major exploration and production firm with significant operations and reserves. Despite a recent revenue decline of -32.18%, the company maintains a strong net margin and ROA, but its ROE is below industry average. Its debt-to-equity ratio is considered healthy.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 8:01 pm

ACN

Six analysts have recently updated their ratings on Accenture (NYSE:ACN), with varying perspectives from bullish to bearish. The average 12-month price target is now $375.5, an 8.68% increase from the previous $345.50. Analysts from firms like Morgan Stanley, BMO Capital, UBS, Wedbush, and Redburn Atlantic have raised their price targets, indicating a positive outlook on Accenture's performance. The company has shown strong financial health with a market capitalization above industry average, a revenue growth rate of 3.03%, a net margin of 12.16%, an ROE of 7.54%, an ROA of 3.84%, and a low debt-to-equity ratio of 0.12.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 8:00 pm